Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA Khondrion Receives Rare Pediatric Disease Designation for Sonlicromanol from US FDA Designation granted for the treatment of MELAS (mitochondrial encephalopathy, lactic acidosis, and stroke-like...

Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential treatment pathway with sonlicromanol Khondrion highlights potential role of inflammatory lipid modulator prostaglandin E2 in COVID-19 disease and proposes potential treatment pathway with sonlicromanol   Elevated levels of PGE2 known to...

Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases Khondrion announces first patients dosed in Phase IIb study of Sonlicromanol for mitochondrial diseases Study will examine impact on cognitive function from one of the most advanced disease-modifying...